According to @DowdEdward, who retweeted @DrHarveyRisch, Dr. Harvey Risch reported that President Trump has appointed him to chair the President's Cancer Panel, with the statement posted on X on Dec 8, 2025 (source: @DowdEdward on X, Dec 8, 2025; source: @DrHarveyRisch on X, Dec 8, 2025). The source posts provide no additional policy details, implementation timelines, funding directives, FDA policy references, or market guidance, and they do not mention cryptocurrency or digital asset market impacts (source: @DowdEdward on X, Dec 8, 2025; source: @DrHarveyRisch on X, Dec 8, 2025). No link to an official White House document or press release is included in the posts, so confirmation beyond the X statements is not provided within the source material (source: @DowdEdward on X, Dec 8, 2025; source: @DrHarveyRisch on X, Dec 8, 2025).

According to @StockMarketNerd, HIMS (HIMS) and the broader biotech sector received honorable mentions in a Dec 8, 2025 post (source: @StockMarketNerd, Dec 8, 2025). According to @StockMarketNerd, the post did not include specific price levels, catalysts, or performance data for HIMS or biotech benchmarks (source: @StockMarketNerd, Dec 8, 2025). According to @StockMarketNerd, no direct implications for the crypto market were cited in the post (source: @StockMarketNerd, Dec 8, 2025).

According to @DowdEdward, former CDC Director Dr. Robert Redfield said he would like mRNA vaccine use curtailed and personally eliminated due to too many unknowns in an EpochTV American Thought Leaders interview scheduled for Dec. 9, 2025, highlighting potential headline risk for health-care and biotech equities; source: @DowdEdward; The Epoch Times. The comments pertain to mRNA COVID-19 products, including Pfizer-BioNTech’s Comirnaty (PFE, BNTX) and Moderna’s Spikevax (MRNA), which the U.S. FDA identifies as mRNA vaccines; source: U.S. Food and Drug Administration. Event-driven headlines of this type are typically monitored by options traders for potential implied-volatility repricing and gap risk in MRNA, PFE, BNTX and NVAX around the broadcast window; source: Cboe Options Institute. Because spot crypto trades continuously, cross-asset sentiment from major health-policy headlines can be reflected in BTC and ETH liquidity during off-hours, so crypto desks may track the interview’s release for any risk-on/off spillover; source: Coinbase Exchange.

According to @CNBC, Novo Nordisk (NVO) shares plunged to a four-year low after the company's Alzheimer's disease drug trial failed to hit a key primary target. CNBC linked the selloff directly to the trial miss in its coverage. CNBC did not mention any direct impact on cryptocurrencies in this update.

According to @CNBC, Novo Nordisk shares fell about 10% after its Alzheimer’s drug trial failed to hit a key target, triggering an immediate downside reaction in the stock (source: CNBC). @CNBC also indicates the report did not cite any direct impact on cryptocurrency markets, leaving digital assets unaffected by this headline based on the information provided (source: CNBC).